-15.0/-6.9mmHg. The same pts on IND had a BP reduction of -6.9/-3.5mmHg on IND. HR reduction in the INN treated pts between 6am-9am was -13.9 bpm and reduction in double product was -3189 compared to -10.4 bpm and -2139 in the INN treated pts during the same period.
Endothelial dysfunction (ED) predicts adverse prognosis in patients with coronary artery disease (CAD) and in hypertensives (HTN). Since reversibility of ED has been reported to be associated with more favorable prognosis in HTN, evaluation of the effect of therapy on ED maybe clinically relevant.
We studied 28 patients (27 men) with controlled HTN and stable asymptomatic CAD while on beta-blocker and nitrate therapy, with evidence of sustained ED assessed by ultrasound measurement of % hyperemic flow-mediated dilation (FMD) of the brachial artery. FMD was evaluated at screening and after a 2 week run-in and only patients with reduced (Ͻ25th percentile of an age and sex-matched normal population) and stable (variation between the 2 measurements within the reproducibility range) FMD were randomized to a double-blind, 2-month treatment period with either placebo (PL) or candesartan cilexitil (C) 16 mg once-daily on top of usual therapy.
No side-effects occurred during the study in either group. At baseline systolic (119ϩ10 vs 126ϩ16 mmHg) and diastolic pressures (79ϩ9 vs 78ϩ8 mmHg) did not significantly differ in the C and PL groups. At the end of treatment diastolic pressure significantly decreased in the C group (72ϩ12; pϽ0.01 vs baseline). Effects of treatment of endothelial function are reported in the Table below. 
